Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Loxo Oncology, Inc.
Report date July 10, 2018 · Filed July 12, 2018
Jointly reported with AISLING CAPITAL III LP, Aisling Capital Partners III LP, Aisling Capital Partners III LLC, ELMS STEVE, SCHIFF ANDREW N
Section 16 reporting ended · disclosed 2018-07-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,038,920 |
Reported balance
After 2018-07-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-10 · Sale · Disposed 1,400,000 · Balance 2,038,920 F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2018 Filed Jul 12, 2018 16:45 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,400,000 | $179.43 | $251,202,000.00 |
DisclosureSEC source: 0000899243-18-019810 · doc4.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,038,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:31 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 250,000 | $80.50 | $20,125,000.00 |
DisclosureSEC source: 0000950142-17-002235 · es1701246_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,438,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 19:29 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500,000 | $75.00 | $37,500,000.00 |
DisclosureSEC source: 0000950142-17-002107 · es1701180_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | PurchaseCommon Stock | 160,000 | $31.00 | $4,960,000.00 |
DisclosureSEC source: 0000950142-17-000108 · es1700164_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.